抗体药物偶联物（ADC）是由抗体和细胞毒性药物通过连接体连接而成的生物靶向药物。这些创新化合物能够将药物精确输送到肿瘤细胞，最大限度地减少对正常组织的伤害，为癌症治疗提供了良好的前景。然而，基于单克隆抗体的 ADC 仍然面临挑战，特别是在平衡功效和安全性方面。双特异性抗体是单克隆抗体的替代品，具有卓越的内化性和选择性，可生产具有更高安全性和治疗功效的 ADC。在这篇综述中，我们提出了有关使用双特异性 ADC 进行癌症治疗的现有证据和未来前景，包括对目前正在进行临床试验的双特异性 ADC 的全面概述。我们对双特异性 ADC 的未来发展提出见解，为癌症治疗提供新策略。© 2024。高等教育出版社。

Antibody-drug conjugates (ADCs) are biologically targeted drugs composed of antibodies and cytotoxic drugs connected by linkers. These innovative compounds enable precise drug delivery to tumor cells, minimizing harm to normal tissues and offering excellent prospects for cancer treatment. However, monoclonal antibody-based ADCs still present challenges, especially in terms of balancing efficacy and safety. Bispecific antibodies are alternatives to monoclonal antibodies and exhibit superior internalization and selectivity, producing ADCs with increased safety and therapeutic efficacy. In this review, we present available evidence and future prospects regarding the use of bispecific ADCs for cancer treatment, including a comprehensive overview of bispecific ADCs that are currently in clinical trials. We offer insights into the future development of bispecific ADCs to provide novel strategies for cancer treatment.© 2024. Higher Education Press.